In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA)

Abstract

The fluorometric microculture cytotoxicity assay (FMCA), a short‐term in vitro assay based on the concept of total tumor cell kill, was used for testing the cytotoxic drug sensitivity of tumor cells from patients with ovarian carcinoma. A total of 125 fresh specimens was obtained, 98 (78%) of which were analyzed successfully. Data from 45 patients were available for clinical correlations. The FMCA appeared to yield clinically relevant cytotoxic drug sensitivity data for ovarian carcinoma as indicated by a comparison with tumor samples obtained from patients with non‐Hodgkin's lymphoma or kidney carcinoma. Considering the most active single agent in vitro actually given in vivo, and using the median drug activity among all ovarian carcinoma samples as a cut‐off, the sensitivity of the assay and its specificity were 75 and 52%, respectively. Cross‐resistance in vitro was frequently observed between standard drugs but not between standard drugs and Taxol. Ten percent of the specimens showed an extreme resistance for at least 4 of 6 of the drugs investigated. Int. J. Cancer 72:1008–1012, 1997. © 1997 Wiley‐Liss, Inc.

Novel activity of acriflavine against colorectal cancer tumor cells

“…(9) OC cells from ascites fluid were collected by centrifugation, followed by purification of the cells by Ficoll-Paque (Pharmacia Biotech) and Percoll densitygradient centrifugation. CLL cells and MNC were isolated from peripheral blood by density gradient centrifugation on 1.077 g ⁄ mL Ficoll-Paque (Pharmacia Biotech) gradient.…”

Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment

“…An additional 96 PCPTCs from different tumor types, and four preparations of normal peripheral blood mononuclear cells (PBMC), detailed in Table 1, were used to determine the activity spectrum of VLX 50 and, for comparison, six standard cytotoxic drugs chosen to represent different mechanistic classes. Tumor cells of ovarian carcinoma were obtained from ascites fluid using standard techniques for tumor cell isolation described in detail previously [13]. Malignant cells from hematological and solid tumors were obtained as described previously [14,15], and briefly in supplementary information section 1.1.…”

Differential activity of cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro

“…The concentracytotoxicity assay (FMCA) have been described previously. 20, 21 Briefly, on Day one 180 mL/well of the tution giving a SI of 50% (IC50) in each cell lines was extracted from dose-response curves by custom-made mor cell preparation (5000 -20,000 cells/well for the cell lines and 10,000 -20,000 and 50,000 -100,000 cells/ computer software in Excel (Microsoft Corporation, Redmond, WA). For CEL, Taxol, and paclitaxel the well for solid and hematologic tumors, respectively) was added to microtiter plates prepared as described.…”